Intra-Cellular Therapies: Downgrade
Zürich (www.aktiencheck.de) - Rating-Update:
Die Analysten der UBS stufen die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN: A1XDTL, Ticker-Symbol: 23I,…
74,250€
1,02%
Echtzeit-Aktienkurs Intra-Cellular Therapies
Bid:
Ask:
Nachrichten zur Intra-Cellular Therapies Aktie
Intra-Cellular Therapies: Kursziel gesteigert
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Mizuho Securities USA bewerten die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN:…
Intra-Cellular Therapies: Klares Upside-Potenzial - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Intra-Cellular Therapies-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…
Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
…
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript
…
Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term Buy
…
Intra-Cellular Therapies has analysts bullish on strong sales trajectory and likely success of depression study
Intra-Cellular Therapies has earned an ‘Outperform’ rating in its initial coverage from Baird analysts who believe the biotechnology company’s strong…
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?
Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Intra-Cellular Therapies gains amid repeated takeover speculation
…
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Call Transcript
…
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 3.97%, respectively, for the quarter ended June 2023. Do the…
Form 10-Q Intra-Cellular Therapies For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022...…
Intra-Cellular Therapies Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: EVP, Chief Medical Officer verkauft Aktien von Intracellular Th im Wert von 119.730$
Durgam, Suresh K. - Vorstand - Tag der Transaktion: 2023-07-17...…
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the…
Form 10-Q Intra-Cellular Therapies For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022...…
Intra-Cellular Therapies Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…
Insiderhandel: Aufsichtsrat verkauft Aktien von Intracellular Th im Wert von 630.000$
Van Nostrand Robert L. - Aufsichtsrat - Tag der Transaktion: 2023-04-17...…
Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intracellular Th im Wert von 847.380$
Neumann, Mark - Vorstand - Tag der Transaktion: 2023-03-28...…
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock…
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
read more...…
Why Intra-Cellular Therapies Climbed Tuesday
The companys depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression....…
Pre-market Movers: Viking Therapeutics, Immuneering, Oscar Health, WiSA Technologies, Intra-Cellular Therapies
LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesdays pre-market trading (as of 08.15…
Intra-Cellular jumps 14% after early data for depression candidate
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular’s stock jumps on new data for depression drug
Shares of Intra-Cellular Therapies Inc. ITCI jumped about 15% in premarket trading on Tuesday after the company said its experimental…
Form 8-K Intra-Cellular Therapies For: Mar 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intracellular Th im Wert von 370.557$
Neumann, Mark - Vorstand - Tag der Transaktion: 2023-03-10...…
Insiderhandel: EVP and General Counsel verkauft Aktien von Intracellular Th im Wert von 330.006$
Halstead, Michael - Vorstand - Tag der Transaktion: 2023-03-13...…
Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intracellular Th im Wert von 169.042$
Neumann, Mark - Vorstand - Tag der Transaktion: 2023-03-13...…
Insiderhandel: EVP, Chief Medical Officer verkauft Aktien von Intracellular Th im Wert von 330.794$
Durgam, Suresh K. - Vorstand - Tag der Transaktion: 2023-03-13...…
Insiderhandel: EVP and General Counsel verkauft Aktien von Intracellular Th im Wert von 720.086$
Halstead, Michael - Vorstand - Tag der Transaktion: 2023-03-10...…
Insiderhandel: SVP of Finance CFO verkauft Aktien von Intracellular Th im Wert von 674.417$
Hineline, Lawrence J. - Vorstand - Tag der Transaktion: 2023-03-10...…
Insiderhandel: Chairman, President & CEO verkauft Aktien von Intracellular Th im Wert von 1.802.566$
Mates, Sharon - Vorstand - Tag der Transaktion: 2023-03-10...…
Insiderhandel: Chairman, President & CEO verkauft Aktien von Intracellular Th im Wert von 925.275$
Mates, Sharon - Vorstand - Tag der Transaktion: 2023-03-13...…